medigraphic.com
SPANISH

Dermatología Cosmética, Médica y Quirúrgica

Órgano oficial de la Sociedad Mexicana de Cirugía Dermatológica y Oncológica, AC
  • Contents
  • View Archive
  • Information
    • General Information        
    • Directory
  • Publish
    • Instructions for authors        
  • medigraphic.com
    • Home
    • Journals index            
    • Register / Login
  • Mi perfil

2018, Number 2

<< Back Next >>

Dermatología Cosmética, Médica y Quirúrgica 2018; 16 (2)

Necrolytic Migratory Erythema as First Manifestation of Glucagonoma Syndrome

Villela-Segura U, Guevara-Sanginés E
Full text How to cite this article

Language: Spanish
References: 10
Page: 142-144
PDF size: 152.29 Kb.


Key words:

necrolytic migratory erythema, glucagonoma syndrome, paraneoplastic syndrome.

ABSTRACT

The necrolytic migratory erythema (nme) represents an entity whose most common association is glucagonoma, a pancreatic tumor derived from alpha cells, the association of these two entities plus a long standing diarrhea and diabetes, is called glucagonoma syndrome; an extremely rare entity, with an estimated incidence of one case per 20 million people. We present a 46 year-old Mexican women, presenting with nme as only clinical finding, where both clinical and pathological correlation were crucial for diagnosis of glucagonoma.


REFERENCES

  1. Tremblay C y Marcil I, Necrolytic migratory erythema: a forgotten paraneoplastic condition, J Cutan Med Surg 2017; 1:1203475417719051

  2. Al-Faouri A, Ajarma K, Alghazawi S et al., Glucagonoma and glucagonoma syndrome: a case report with review of recent advances in management, Case Rep Surg 2016; 16:1484-89.

  3. Han X, Wang D, Kuang T et al., Glucagonoma syndrome: report of one case, Transl Gastroenterol Hepatol 2016; 1:70.

  4. Wu S, Bai J, Xu J et al., Necrolytic migratory erythema as the first manifestation of pancreatic neuroendocrine tumor, World J Surg Oncol 2014; 12:220.

  5. Gronau M, Jäger D, Enk AH et al., Necrolytic migratory erythema in a patient with neuroendocrine carcinoma, Intern Med 2013; 52:151-2.

  6. John AM y Schwartz RA, Glucagonoma syndrome: a review and update on treatment, J Eur Acad Dermatol Venereol 2016; 30:2016-22.

  7. Tseng HC, Liu CT, Ho JC et al., Necrolytic migratory erythema and glucagonoma rising from pancreatic head, Pancreatology 2013; 13:455-7.

  8. Thomaidou E, Nahmias A, Gilead L et al., Rapid clearance of necrolytic migratory erythema following intravenous administration of amino acids, jama Dermatol 2016; 152:345-6.

  9. Kimbara S, Fujiwara Y, Toyoda M et al., Rapid improvement of glucagonoma- related necrolytic migratory erythema with octreotide, Clin J Gastroenterol 2014; 7:255-9.

  10. Luber AJ, Ackerman LS, Culpepper KS et al., Paediatric necrolytic migratory erythema as a presenting sign of glucagonoma syndrome, Br J Dermatol 2016; 174:1092-95.




2020     |     www.medigraphic.com

Mi perfil

C?MO CITAR (Vancouver)

Dermatología Cosmética, Médica y Quirúrgica. 2018;16